EMA/35341/2023
EMADOC-1829012207-54328

Boey (*trenibotulinumtoxinE*)

A plain-language overview of Boey and why it is authorised in the EU

What is Boey and what is it used for?

Boey is a medicine used to temporarily improve the appearance of vertical frown lines between the eyebrows. It is used in adults with moderate to severe facial lines when these lines have a significant psychological impact.

Boey contains the active substance trenibotulinumtoxinE.

How is Boey used?

The medicine can only be obtained with a prescription and should be given by a doctor with the appropriate qualifications and expertise in the treatment of vertical lines between the eyebrows.

Boey is given by injection into the muscles in the forehead whose contractions cause the vertical lines between the eyebrows. The medicine is injected into the muscle in 5 different places above and between the eyebrows.

Boey has an early onset of effect and short duration and should be used occasionally.

For more information about using Boey, see the package leaflet or contact your doctor or pharmacist.

How does Boey work?

The active substance in Boey, trenibotulinumtoxinE, is produced by the bacterium *Clostridium botulinum*. The toxin reduces the release of acetylcholine, a chemical messenger that causes muscles to contract. When Boey is injected directly into the muscles above and between the eyebrows, it causes the muscles to relax, helping to make the vertical lines less noticeable.

What benefits of Boey have been shown in studies?

Boey has been shown to make the vertical lines between the eyebrows less noticeable in two main studies involving 725 adults with moderate or severe vertical lines that affected their mood or caused symptoms of anxiety or depression.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

In both studies, Boey was compared with placebo (a dummy treatment). The effectiveness of treatment was measured using a standard 4-point scale, called facial wrinkle scale (FWS), where 0 = no lines, 1 = mild, 2 = moderate and 3 = severe.

Seven days after treatment, 72.6% of adults (386 out of 532) treated with Boey were assessed by the study doctor as having either mild or no vertical lines with at least a 2 grade improvement between the eyebrows, compared with 0.5% (1 out of 193) of those receiving placebo. When asked to assess their own appearance, 63.1% of adults (335 out of 532) reported improvement with Boey, compared with 0.5% (1 out of 193) in the placebo group.

Studies carried out with Boey are described in more detail in the medicine's assessment report.

What are the side effects and restrictions with Boey?

For the full list of side effects and restrictions with Boey, see the package leaflet.

The most common side effects with Boey (which may affect up to 1 in 100 people) include drooping eyelids, drooping eyebrows, and in rare cases, Mephisto sign (an exaggerated arching of the eyebrows).

Boey must not be used in people who are hypersensitive (allergic) to any botulinum toxin preparation. It must also not be used in people with diseases affecting the muscles, such as myasthenia gravis or Eaton-Lambert syndrome, and those who have an infection or inflammation at the planned site of injection.

Why is Boey authorised in the EU?

Boey is more effective than placebo in adults with moderate to severe vertical lines between the eyebrows, with a peak effect after 7 days. The observed side effects were generally mild and non-serious and are similar to those seen with other botulinum toxin medicines.

The European Medicines Agency decided that Boey's benefits are greater than its risks when used occasionally and it can be authorised for use in the EU.

What measures are being taken to ensure the safe and effective use of Boey?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Boey have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Boey are continuously monitored. Suspected side effects reported with Boey are carefully evaluated and any necessary action is taken to protect patients.

Other information about Boey

Boey received a marketing authorisation valid throughout the EU on 15 July 2026.

Further information on Boey, including the package leaflet and assessment report(s), can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/boey

For information about the availability of this medicine in your country, contact your national competent authority.

This overview was last updated in 06-2026.